<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01914159</url>
  </required_header>
  <id_info>
    <org_study_id>N-037.0156</org_study_id>
    <nct_id>NCT01914159</nct_id>
  </id_info>
  <brief_title>Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study</brief_title>
  <acronym>RIP</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Ranibizumab in Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration
      (RIP) Study is a prospective, multicenter, uncontrolled, interventional phase 2 clinical
      trial that investigates the effect of fixed monthly intravitreal injections of ranibizumab
      (Lucentis, Novartis Pharma, Germany) on visual acuity and retinal morphology over a study
      period of 12 months in 30 patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best-corrected visual acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Early Treatment of Diabetic Retinopathy Study (ETDRS) protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal morphology</measure>
    <time_frame>12 months</time_frame>
    <description>Spectral-domain optical coherence tomography (SD-OCT), fundus autofluorescence imaging, fluorescence angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual field</measure>
    <time_frame>12 months</time_frame>
    <description>Microperimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual function quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Visual function questionary 25 (VFL-25)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)</intervention_name>
    <description>Monthly intravitreal injections</description>
    <arm_group_label>Ranibizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of a pigment epithelial tear secondary to age-related macular degeneration

          -  Written informed consent

        Exclusion Criteria:

          -  Time of diagnosis more than 6 months before study recruitment

          -  Ocular surgery of the study eye within 1 month before study recruitment

          -  Extensive subretinal fibrosis or retinal atrophy of the study eye

          -  Significant opacification of optical media of the study eye

          -  Uncontrolled glaucoma of the study eye

          -  Active ocular inflammation of the study eye

          -  Best-corrected visual acuity of the contralateral eye below 20/200

          -  Concurrent ocular or systemic therapy with other vascular endothelial growth factor
             (VEGF)-inhibitory drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Bonn, Department of Ophthalmology</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of M端nchen (LMU), Department of Ophthalmology</name>
      <address>
        <city>M端nchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universityof M端nster, Department of Ophthalmology</name>
      <address>
        <city>M端nster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2013</study_first_submitted>
  <study_first_submitted_qc>July 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2013</study_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Frank G. Holz</investigator_full_name>
    <investigator_title>Director, Department of Ophthalmology, University of Bonn</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

